Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke

Five healthy men were passively exposed under pre‐ and postplacebo controlled conditions to sidestream smoke from four and 16 standard marijuana cigarettes (2.8% delta‐9‐tetrahydrocannabinol [Δ‐9‐THC]) for 1 hour each day for 6 consecutive days. Subjective effects produced by the 16‐cigarette exposure conditions were similar to those observed after active smoking of one 2.8% Δ‐9‐THC marijuana cigarette. Effects after the four‐cigarette condition were less pronounced. Concurrent physiologic measurements showed no clear trends or effects of smoke exposure for either condition. Daily mean plasma levels of Δ‐9‐THC ranged from 2.4 to 7.4 ng/ml with an individual high of 18.8 ng/ml for the 16‐cigarette condition. With the use of EMIT cannabinoid assays with 20 ng/ml (EMIT 20) and 100 ng/ml (EMIT 100) cutoffs, urines positive per subject under the four‐ and 16‐cigarette passive exposure conditions were 4.6 ± 2.2 and 35.2 ± 3.8, respectively, for the EMIT 20 and 0.0 and 1.0 ± 0.8, respectively, for the EMIT 100 assay. From the results of these studies, caution is clearly indicated for individuals who might be substantially exposed to heavy marijuana cigarette smoke environments and for those interpreting marijuana screening data.

[1]  G. Barnett,et al.  Marijuana effect and delta‐9‐tetrahydrocannabinol plasma level , 1984, Clinical pharmacology and therapeutics.

[2]  A. P. Mason,et al.  Cannabinoids in plasma after passive inhalation of marijuana smoke. , 1983, JAMA.

[3]  A. P. Mason,et al.  Cannabinoid concentrations in plasma after passive inhalation of marijuana smoke. , 1983, Journal of analytical toxicology.

[4]  L. Hollister,et al.  Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. , 1981, Psychopharmacology.

[5]  B. Sadler,et al.  Metabolism, disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women , 1983, Clinical pharmacology and therapeutics.

[6]  R. Hawks,et al.  The analysis of cannabinoids in biological fluids. , 1982, NIDA research monograph.

[7]  A. P. Mason,et al.  Ethanol, marijuana, and other drug use in 600 drivers killed in single-vehicle crashes in North Carolina, 1978-1981. , 1984, Journal of forensic sciences.

[8]  W. Martin,et al.  Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test. , 1961, The Journal of pharmacology and experimental therapeutics.

[9]  G. Nahas,et al.  Marijuana intoxication by passive inhalation: documentation by detection of urinary metabolites. , 1977, The American journal of psychiatry.

[10]  C. Cook,et al.  Radioimmunoassays for cannabinoids. , 1982, NIDA research monograph.

[11]  R. Falck Passive inhalation of marijuana smoke. , 1983, JAMA.

[12]  M. Pérez-Reyes,et al.  Comparison of effects of marihuana cigarettes of three different potencies , 1982, Clinical pharmacology and therapeutics.

[13]  J. Mendelson,et al.  Marijuana consumption and tolerance to physiological and subjective effects. , 1975, Archives of general psychiatry.

[14]  C. Haertzen An Overview of Addiction Research Center Inventory Scales (ARCI): An Appendix and Manual of Scales. , 1974 .

[15]  J. Mørland,et al.  Cannabinoids in blood and urine after passive inhalation of Cannabis smoke. , 1985, Journal of forensic sciences.

[16]  Robert A. Nowlan,et al.  Tolerance to marijuana: Heart rate and subjective “high” , 1977, Clinical pharmacology and therapeutics.

[17]  E. G. Williams,et al.  Studies on marihuana and pyrahexyl compound. , 1946, Public health reports.

[18]  L. Hollister,et al.  Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? , 1981, Journal of clinical pharmacology.

[19]  A. Mann,et al.  An EMIT assay for cannabinoid metabolites in urine. , 1982, NIDA research monograph.

[20]  M. Pérez-Reyes,et al.  Passive inhalation of marijuana smoke and urinary excretion cannabinoids. , 1983, JAMA.

[21]  L. J. King,et al.  Passive inhalation of cannabis smoke , 1984, The Journal of pharmacy and pharmacology.

[22]  L. Hollister,et al.  Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking , 1980, Clinical pharmacology and therapeutics.